Changeflow GovPing Healthcare & Life Sciences Al18F-NOTA-FAPI PET/CT Imaging for Malignant Tu...
Routine Notice Added Final

Al18F-NOTA-FAPI PET/CT Imaging for Malignant Tumors (NCT05749302)

Email

Summary

ClinicalTrials.gov registry entry NCT05749302 for a Phase 3 interventional study evaluating Al18F-NOTA-FAPI PET/CT imaging in participants with malignant tumors. The trial is registered on ClinicalTrials.gov, operated by the National Library of Medicine under NIH, and classified as Phase 3.

Published by NIH on clinicaltrials.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors ClinicalTrials.gov - Phase 3 Oncology Trials for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 3 changes logged to date.

What changed

ClinicalTrials.gov registry entry for Phase 3 trial NCT05749302 evaluating Al18F-NOTA-FAPI PET/CT imaging as a diagnostic tool for malignant tumors. The registration provides study metadata including trial identifier, condition (cancer), phase classification (Phase 3), and sort parameters. The Al18F-NOTA-FAPI radiopharmaceutical targets fibroblast activation protein (FAP) for PET/CT imaging of tumors.

Affected parties include clinical investigators conducting oncology imaging trials, sponsors of radiopharmaceutical trials, and healthcare institutions conducting Phase 3 cancer imaging studies. This registration establishes a public record of the trial but imposes no compliance obligations beyond standard clinical trial registration requirements.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Show glossary

Get daily alerts for ClinicalTrials.gov - Phase 3 Oncology Trials

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NIH.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NIH
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Clinical investigators Healthcare providers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing 3345 Medical Device Manufacturing
Activity scope
Clinical trial registration Diagnostic imaging research Oncology PET/CT studies
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Clinical Operations
Topics
Medical Devices Pharmaceuticals

Get alerts for this source

We'll email you when ClinicalTrials.gov - Phase 3 Oncology Trials publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!